Skip to the content
Altai Oncology - Softwarelogo darklogo light
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us
Altai Oncology - Softwarelogo darklogo light
Breast Cancer

New Protocol: Pembrolizumab with Chemotherapy in Triple-Negative Breast Cancer

Ulas D. Bayraktar, MD
2022-11-26
Other diagnosis

New Indication: Avelumab and Axitinib in Thymic Carcinoma

Ulas D. Bayraktar, MD
2022-11-26
Non-Small Cell Lung Cancer

New Indication: Adjuvant Pembrolizumab in NSCLC

Ulas D. Bayraktar, MD
2022-11-26
Non-Small Cell Lung Cancer

New Drug: Selpercatinib in RET-Fusion Positive NSCLC

Ulas D. Bayraktar, MD
2022-11-26
Diffuse Large B Cell Lymphoma

New Indication: Polatuzumab in Untreated DLBCL

Ulas D. Bayraktar, MD
2022-11-26
Acute myeloid leukemia

New Drug: Enasidenib for IDH2 Mutant AML

Ulas D. Bayraktar, MD
2022-09-20
Gastrointestinal Stromal Tumor

New Drug: Ripretinib for Advanced GIST

Ulas D. Bayraktar, MD
2022-09-20
Non-Small Cell Lung Cancer

New Indication: Neoadjuvant Nivolumab for NSCLC

Ulas D. Bayraktar, MD
2022-09-20
Mantle cell lymphoma

New Protocol: Ibrutinib with Rituximab and Bendamustine for Mantle Cell Lymphoma

Ulas D. Bayraktar, MD
2022-09-20
Follicular Lymphoma

New Protocol: Lenalidomide-Rituximab for Untreated Follicular Lymphoma

Ulas D. Bayraktar, MD
2022-09-20

Posts pagination

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
  • Library
  • F.A.Q.
  • Contact Us

Privacy Policy

Altai, Inc (USA)

30 N Gould St, Ste 6801

Sheridan, WY, 82801, USA

Phone: +1 (978) 393 0042

Altay Tıp Sağlık Yazılım AŞ (Türkiye)

Mutlukent Mah Manuk Bey Sk No: 4

Çankaya, Ankara, 06800, Türkiye

Phone: +90 (312) 911 5735

Our Terms & Privacy Policy

Copyright - 2024 - Altai Inc - All rights reserved

Back to top Drag
  • Library
  • Articles
  • Patient Education
  • F.A.Q.
  • Contact Us

jghghjghjghhgj